Compass to Care, The Mike & Sandy Ernsdorff Childhood Cancer Foundation announced today it has received a $50,000 grant from Belgium-based IBA. Funds are to help children with cancer travel to access proton therapy treatment.
Proton therapy is a form of radiotherapy considered by many specialists to be the most advanced and targeted cancer treatment. According to the University of Florida Proton Therapy Center, pediatric proton therapy is ideal for tumors located near growing tissues in the spinal cord and brain, eyes, ears or mouth because protons can be precisely controlled. For sarcomas and lymphomas, proton therapy may also deliver less radiation to the heart, lungs, and intestines. Healthy tissues surrounding the pediatric cancer are spared from excess radiation, meaning physicians can deliver more potent doses of radiation directly to the child’s tumor.
IBA is the worldwide leader in cancer radiation therapy. 65% of all proton therapy patients have been treated using IBA technology to date. The company has been leading proton therapy for the last 30 years and has built the largest user community in the world. The company, based in Belgium, also has offices in the United States, Germany, China, and Russia.
“An average proton therapy treatment lasts 6-8 weeks. Quite often parents, who are not local, end up relocating close to the treatment facility for the entire duration. As a result, the travel and lodging expenses can end up costing families thousands and thousands of dollars,” commented Compass to Care founder, Michelle Ernsdorff. “When these families are referred to Compass to Care for support, they are trying to figure out how they can afford the treatment, the time off of work, and added travel expenses. We are truly grateful to have the support of IBA, who ensures these travel expenses do not stand in the way of getting children this vital treatment. We could not help these children without IBA standing by our side,” she added.
At IBA we dare to develop innovative solutions pushing back the limits of science. We share ideas and know-how with our customers, our partners and leading experts to bring new solutions for the diagnosis and treatment of cancer and for the benefits of patients. We care of the well-being of patients and stakeholders as it is together that we complete our mission to Protect Enhance and Saves lives.